Compare CAAS & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAAS | SPRO |
|---|---|---|
| Founded | N/A | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.6M | 136.7M |
| IPO Year | N/A | 2017 |
| Metric | CAAS | SPRO |
|---|---|---|
| Price | $4.52 | $2.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 22.7K | ★ 261.3K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.68 | N/A |
| EPS | ★ 1.11 | N/A |
| Revenue | ★ $725,260,000.00 | $40,549,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.04 | ★ N/A |
| Revenue Growth | ★ 16.72 | N/A |
| 52 Week Low | $3.50 | $0.51 |
| 52 Week High | $5.37 | $3.22 |
| Indicator | CAAS | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 68.95 | 65.92 |
| Support Level | $4.24 | $2.26 |
| Resistance Level | $4.60 | $2.66 |
| Average True Range (ATR) | 0.13 | 0.09 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 93.33 | 76.68 |
China Automotive Systems Inc is a holding company. The firm through its subsidiary is a supplier of power steering systems and components to China's automotive industry. Its product offering encompasses a full range of auto parts incorporated into steering systems for both passenger automobiles and commercial vehicles. The company offers four separate series, models of power steering including rack and pinion power steering, integral power steering, electronic power steering and manual steering, steering columns, steering oil pumps, and steering hoses. Geographically, it derives a majority of its revenue from China.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.